Drug
Avelumab
Avelumab: highest development phase Phase 3, developed by Merck KGaA. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| Avelumab NCT02625623 | Phase 3 | Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
| Avelumab NCT02576574 | Phase 3 | First Line Non-Small Cell Lung Cancer |
| Avelumab NCT03389126 | Phase 2 | Carcinoma, Hepatocellular |
| Avelumab NCT03278405 | Phase 1/2 | Neuroendocrine Carcinoma |
| Avelumab NCT03451825 | Phase 1 | Refractory or Relapsed Solid Tumors |
| Avelumab NCT05081180 | Phase 1 | Central Nervous System Tumors |
Latest
No recent events.
Follow Avelumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.